Table 1. Demographics and baseline characteristics of the patients.
| Placebo (N = 16) | Tesamorelin 1mg (N = 18) | Tesamorelin 2mg (N = 19) | P value | |
|---|---|---|---|---|
| Age (years) | 63.1±7.0 | 59.5±7.9 | 60.3±6.7 | 0.40 |
| Gender (n, %) | ||||
| Male | 12 (75) | 9 (50) | 14 (74) | 0.22 |
| Female | 4 (25) | 9 (50) | 5 (26) | |
| Race (n, %) | ||||
| Caucasian | 12 (75) | 7 (39) | 10 (53) | 0.25 |
| Hispanic/Latino | 3 (19) | 7 (39) | 6 (32) | |
| Asian/Pacific Islander | 0 | 3 (17) | 3 (16) | |
| Other | 1 (6) | 1 (6) | 0 | |
| Weight (kg) | 91±15 | 91±16 | 95±18 | 0.64 |
| BMI (kg/m2) | 30.3±4.2 | 32.2±4.2 | 32.1±4.2 | 0.32 |
| Fasting glucose (mmol/L) | 6.9±2.5 | 8.7±2.4 | 7.7±1.4 | 0.09 |
| Fasting insulin (pmol/L) | 86±41 | 168±12 | 100±68 | 0.02 |
| Relative Insulin Response (L/pmol) | 0.26±0.27 | 0.15±0.27 | 0.07±0.45 | 0.34 |
| HbA1c (%) | 6.8±0.9 | 7.4±0.9 | 6.9±0.7 | 0.16 |
| Insulin status (n, %) | ||||
| Users | 4 (25) | 5 (28) | 5 (26) | >0.99 |
| Non-users | 12 (75) | 13 (72) | 14 (74) |
Abbreviations: BMI, body mass index. Data are presented as mean ± SD unless otherwise specified.